Zuventus Healthcare Limited has issued a formal clarification countering false and misleading communications about its future, underlining the broader importance of transparency and trust in India’s healthcare and pharmaceutical policy environment.
The company categorically denied rumours of closure or rebranding, stating that there has been no shutdown, suspension, or transfer of business assets. Zuventus confirmed that its field staff continues to operate at full strength across the country, signalling uninterrupted production, distribution, and market engagement—key indicators of operational stability in a sector that plays a critical role in public health delivery.
Zuventus also clarified that it has no association or affiliation with any entity named Zorvia Healthcare Limited, describing such claims as inaccurate and misleading. From a policy perspective, the company noted that misinformation can disrupt stakeholder confidence, affect workforce stability, and undermine trust in regulated healthcare markets.
Founded in 2002, Zuventus Healthcare is a subsidiary of Emcure Pharmaceuticals, which is listed on the Bombay Stock Exchange and the National Stock Exchange. The company reiterated its responsibility to develop, manufacture, and market high-quality and affordable medicines, aligning with national policy priorities on access, affordability, and quality healthcare.
Zuventus said it is actively pursuing appropriate legal remedies to protect its goodwill and stakeholder interests, reflecting the growing emphasis on regulatory compliance and brand protection. With a diversified portfolio across cardiology, diabetology, gastroenterology, orthopaedics, pain management, and nutraceuticals, supported by robust manufacturing standards and a growing field force, the company said its long-term fundamentals remain aligned with India’s healthcare and economic policy goals.